Hologic Company Profile (NASDAQ:HOLX)

About Hologic (NASDAQ:HOLX)

Hologic logoHologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:HOLX
  • CUSIP: 43644010
  • Web: www.hologic.com
  • Market Cap: $10.17558 billion
  • Outstanding Shares: 280,473,000
Average Prices:
  • 50 Day Moving Avg: $37.64
  • 200 Day Moving Avg: $41.89
  • 52 Week Range: $35.15 - $46.80
  • Trailing P/E Ratio: 13.37
  • Foreward P/E Ratio: 16.78
  • P/E Growth: 2.03
Sales & Book Value:
  • Annual Revenue: $2.98 billion
  • Price / Sales: 3.38
  • Book Value: $10.23 per share
  • Price / Book: 3.51
  • EBITDA: $1.01 billion
  • Net Margins: 25.65%
  • Return on Equity: 23.18%
  • Return on Assets: 7.39%
  • Debt-to-Equity Ratio: 0.78%
  • Current Ratio: 0.85%
  • Quick Ratio: 0.65%
  • Average Volume: 3.26 million shs.
  • Beta: 0.91
  • Short Ratio: 5.07

Frequently Asked Questions for Hologic (NASDAQ:HOLX)

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. The firm earned $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm's quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the firm posted $0.51 EPS. View Hologic's Earnings History.

When will Hologic make its next earnings announcement?

Hologic is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its fourth quarter earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of $0.48-0.50 for the period, compared to the Thomson Reuters consensus estimate of $0.50. The company issued revenue guidance of $785-800 million, compared to the consensus revenue estimate of $817.04 million.

Where is Hologic's stock going? Where will Hologic's stock price be in 2017?

13 equities research analysts have issued 1-year price targets for Hologic's shares. Their predictions range from $42.00 to $53.00. On average, they anticipate Hologic's share price to reach $47.77 in the next twelve months. View Analyst Ratings for Hologic.

What are analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

  • 1. According to Zacks Investment Research, "Hologic is optimistic about the recent commercial launch of the Brevera breast biopsy system in the United States. Hologic’s third-quarter 2017 performance was quite promising with revenues and earnings beating the estimates. The company’s top-line growth was led by strength in the molecular diagnostics and GYN Surgical businesses. Moreover, sales were driven by the company’s recent receipt of CE mark for its new Panther Fusion system and Panther Fusion assays for flu and respiratory testing. On the flip side, Hologic has been trading below the broader industry over the last six months. Moreover, the lowered guidance suggests dull prospects. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges." (10/3/2017)
  • 2. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 10/2/17. The number of digital breast tomosynthesis (DBT) units increased by 118 during September which represents a (4.1%) Y/Y decrease. DBT unit penetration increased to 28.5% from 28.0% last month and facility penetration increased to 42.8% from 42.0% last month. More importantly, DBT units placements were up 5.9% in F4Q17 vs. F4Q16. Based on this, we think that HOLX’s Breast Health business could see improved growth in F4Q17." (10/2/2017)

Who are some of Hologic's key competitors?

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

  • Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer
  • Robert W. McMahon, Chief Financial Officer
  • Sanjay Prabhakaran, Regional President - Asia
  • Peter J. Valenti III, Division President- Breast and Skeletal Health
  • Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
  • Thomas A. West, Division President- Diagnostics
  • Eric B. Compton, Chief Operating Officer
  • Michael J. Watts, Vice President, IR Contact Officer
  • John M. Griffin, General Counsel
  • Elaine S. Ullian, Lead Independent Director

Who owns Hologic stock?

Hologic's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Curbstone Financial Management Corp (0.01%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Who bought Hologic stock? Who is buying Hologic stock?

Hologic's stock was acquired by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp. View Insider Buying and Selling for Hologic.

How do I buy Hologic stock?

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of Hologic stock can currently be purchased for approximately $35.90.

MarketBeat Community Rating for Hologic (NASDAQ HOLX)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  525 (Vote Outperform)
Underperform Votes:  359 (Vote Underperform)
Total Votes:  884
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Hologic (NASDAQ:HOLX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.69)
Consensus Price Target: $47.77 (33.06% upside)
Consensus Price Target History for Hologic (NASDAQ:HOLX)
Price Target History for Hologic (NASDAQ:HOLX)
Analysts' Ratings History for Hologic (NASDAQ:HOLX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/10/2017Jefferies Group LLCReiterated RatingBuy$49.00 -> $44.00N/AView Rating Details
10/9/2017Stifel NicolausReiterated RatingBuy -> Buy$48.00 -> $45.00N/AView Rating Details
10/2/2017Needham & Company LLCReiterated RatingBuy$50.00MediumView Rating Details
9/22/2017Royal Bank Of CanadaReiterated RatingHold$42.00LowView Rating Details
8/9/2017Barclays PLCReiterated RatingEqual Weight$53.00 -> $51.00LowView Rating Details
8/3/2017Deutsche Bank AGLower Price TargetBuy$51.00 -> $49.00MediumView Rating Details
8/3/2017Goldman Sachs Group, Inc. (The)DowngradeConviction-Buy -> Buy$48.00 -> $47.00HighView Rating Details
7/21/2017Bank of America CorporationReiterated RatingNeutral$44.00 -> $48.00LowView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$51.00MediumView Rating Details
5/14/2017BTIG ResearchReiterated RatingBuy$47.00LowView Rating Details
5/9/2017Canaccord GenuityReiterated RatingBuy$53.00LowView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
1/4/2017Evercore ISIDowngradeBuy -> Hold$42.00N/AView Rating Details
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 -> $40.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
1/28/2016J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
10/26/2015GabelliInitiated CoverageBuy$43.00N/AView Rating Details
10/21/2015Craig HallumDowngradeBuy -> Hold$42.00 -> $37.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Hologic (NASDAQ:HOLX)
Earnings by Quarter for Hologic (NASDAQ:HOLX)
Earnings History by Quarter for Hologic (NASDAQ HOLX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017$0.49N/AView Earnings Details
8/2/2017Q3 2017$0.49$0.50$799.70 million$806.10 millionViewListenView Earnings Details
5/10/2017Q2 17$0.46$0.50$685.24 million$715.40 millionViewN/AView Earnings Details
2/1/2017Q117$0.51$0.52$725.01 million$734.40 millionViewListenView Earnings Details
11/2/2016Q416$0.50$0.52$721.52 million$726.80 millionViewN/AView Earnings Details
7/27/2016Q316$0.48$0.51$703.66 million$717.40 millionViewListenView Earnings Details
4/27/2016Q216$0.46$0.47$686.82 million$693.30 millionViewListenView Earnings Details
1/27/2016Q116$0.42$0.46$688.68 million$695.20 millionViewListenView Earnings Details
11/4/2015Q415$0.42$0.43$691.94 million$702.80 millionViewListenView Earnings Details
7/29/2015Q315$0.39$0.43$653.85 million$693.90 millionViewListenView Earnings Details
4/29/2015Q215$0.39$0.41$646.49 million$655.50 millionViewN/AView Earnings Details
1/28/2015Q115$0.36$0.39$630.79 million$652.80 millionViewListenView Earnings Details
11/5/2014Q414$0.37$0.43$636.20 million$660.60 millionViewListenView Earnings Details
7/30/2014Q314$0.34$0.37$621.89 million$632.60 millionViewListenView Earnings Details
4/30/2014Q214$0.33$0.37$609.35 million$625.00 millionViewListenView Earnings Details
2/3/2014Q114$0.31$0.34$609.65 million$612.40 millionViewListenView Earnings Details
11/11/2013Q413$0.37$0.39$624.40 million$622.10 millionViewListenView Earnings Details
8/5/2013Q3 2013$0.37$0.38$627.05 million$626.10 millionViewListenView Earnings Details
5/6/2013Q2 2013$0.34$0.35$639.53 million$619.10 millionViewListenView Earnings Details
2/4/2013Q1 2013$0.37$0.38$646.52 million$644.60 millionViewListenView Earnings Details
11/12/2012Q412$0.36$0.37$581.12 million$600.20 millionViewN/AView Earnings Details
7/30/2012$0.34$0.35ViewN/AView Earnings Details
4/30/2012$0.33$0.33ViewN/AView Earnings Details
1/30/2012$0.32$0.34ViewN/AView Earnings Details
11/7/2011$0.33$0.34ViewN/AView Earnings Details
8/1/2011$0.32$0.32ViewN/AView Earnings Details
5/2/2011$0.28$0.30ViewN/AView Earnings Details
1/31/2011$0.28$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Hologic (NASDAQ:HOLX)
2017 EPS Consensus Estimate: $2.00
2018 EPS Consensus Estimate: $2.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$0.50$0.51$0.51
Q2 20173$0.46$0.53$0.49
Q3 20173$0.48$0.54$0.50
Q4 20174$0.49$0.55$0.51
Q1 20183$0.52$0.52$0.52
Q2 20183$0.52$0.55$0.53
Q3 20183$0.51$0.57$0.54
Q4 20183$0.52$0.55$0.53
(Data provided by Zacks Investment Research)


Dividend History for Hologic (NASDAQ:HOLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Hologic (NASDAQ:HOLX)
Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 96.38%
Insider Trades by Quarter for Hologic (NASDAQ:HOLX)
Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)
Insider Trades by Quarter for Hologic (NASDAQ:HOLX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2017Lawrence M LevyDirectorSell9,596$36.81$353,228.76View SEC Filing  
10/9/2017Lawrence M LevyDirectorSell7,138$37.38$266,818.44View SEC Filing  
9/7/2017Lawrence M. LevyDirectorSell7,139$39.04$278,706.56View SEC Filing  
8/3/2017Elaine UllianDirectorSell6,902$40.12$276,908.24View SEC Filing  
7/17/2017Karleen Marie ObertonVPSell4,704$45.19$212,573.76View SEC Filing  
7/3/2017Elaine UllianDirectorSell8,849$45.28$400,682.72View SEC Filing  
6/7/2017Lawrence M LevyDirectorSell2,960$44.54$131,838.40View SEC Filing  
6/2/2017Elaine UllianDirectorSell8,938$43.99$393,182.62View SEC Filing  
5/30/2017Peter J Valenti IIIInsiderSell10,005$43.44$434,617.20View SEC Filing  
5/24/2017Lawrence M LevyDirectorSell9,193$42.93$394,655.49View SEC Filing  
5/17/2017Lawrence M LevyDirectorSell9,076$42.80$388,452.80View SEC Filing  
5/10/2017Lawrence M LevyDirectorSell9,837$45.34$446,009.58View SEC Filing  
5/3/2017Lawrence M LevyDirectorSell10,203$45.00$459,135.00View SEC Filing  
4/26/2017Lawrence M LevyDirectorSell10,374$44.46$461,228.04View SEC Filing  
4/24/2017Sally CrawfordDirectorSell16,969$44.00$746,636.00View SEC Filing  
4/19/2017Lawrence M LevyDirectorSell10,836$42.49$460,421.64View SEC Filing  
4/12/2017Lawrence M LevyDirectorSell10,757$42.45$456,634.65View SEC Filing  
4/3/2017Elaine UllianDirectorSell9,104$42.40$386,009.60View SEC Filing  
3/8/2017Sally CrawfordDirectorSell17,396$42.00$730,632.00View SEC Filing  
2/3/2017Elaine UllianDirectorSell9,423$39.54$372,585.42View SEC Filing  
11/21/2016Karleen Marie ObertonVPSell3,023$38.32$115,841.36View SEC Filing  
11/15/2016Karleen Marie ObertonVPSell1,211$36.55$44,262.05View SEC Filing  
11/8/2016Karleen Marie ObertonVPSell984$38.57$37,952.88View SEC Filing  
11/7/2016Karleen Marie ObertonVPSell522$38.53$20,112.66View SEC Filing  
10/10/2016Elaine UllianDirectorSell18,236$39.88$727,251.68View SEC Filing  
10/10/2016Karleen Marie ObertonVPSell31,470$40.00$1,258,800.00View SEC Filing  
7/21/2016Nancy LeamingDirectorSell8,179$37.00$302,623.00View SEC Filing  
7/11/2016Nancy LeamingDirectorSell6,221$36.04$224,204.84View SEC Filing  
6/1/2016Lawrence M LevyDirectorSell17,794$34.41$612,291.54View SEC Filing  
5/27/2016Peter J Valenti IIIInsiderSell10,022$33.83$339,044.26View SEC Filing  
5/26/2016Elaine UllianDirectorSell6,896$33.85$233,429.60View SEC Filing  
5/26/2016Karleen Marie ObertonVPSell4,228$33.85$143,117.80View SEC Filing  
2/24/2016David R Lavance JrDirectorSell11,621$34.50$400,924.50View SEC Filing  
11/10/2015Lawrence M. LevyDirectorSell20,000$40.70$814,000.00View SEC Filing  
9/21/2015Lawrence M. LevyDirectorSell5,000$42.02$210,100.00View SEC Filing  
9/8/2015Wayne WilsonDirectorSell100,000$39.00$3,900,000.00View SEC Filing  
8/28/2015Wayne WilsonDirectorSell11,146$39.70$442,496.20View SEC Filing  
8/26/2015Wayne WilsonDirectorSell25,080$38.61$968,338.80View SEC Filing  
8/14/2015Wayne WilsonDirectorSell13,257$42.20$559,445.40View SEC Filing  
6/3/2015Lawrence M LevyDirectorSell10,000$36.45$364,500.00View SEC Filing  
5/22/2015Lawrence M LevyDirectorSell5,000$35.05$175,250.00View SEC Filing  
5/4/2015Lawrence M LevyDirectorSell10,000$34.36$343,600.00View SEC Filing  
3/6/2015David R Lavance JrDirectorSell12,000$32.12$385,440.00View SEC Filing  
2/13/2015David R Lavance JrDirectorSell8,000$30.32$242,560.00View SEC Filing  
1/29/2015Karleen Marie ObertonVPSell18,997$30.00$569,910.00View SEC Filing  
11/11/2014Karleen Marie ObertonVPSell2,609$26.30$68,616.70View SEC Filing  
11/3/2014Karleen Marie ObertonVPSell12,507$26.83$335,562.81View SEC Filing  
10/31/2014Roger D MillsSVPSell14,506$26.00$377,156.00View SEC Filing  
9/9/2014Elaine UllianDirectorBuy7,900$25.36$200,344.00View SEC Filing  
5/9/2014Rohan HastieSVPSell6,037$24.36$147,061.32View SEC Filing  
5/8/2014Glenn MuirCFOSell50,000$24.26$1,213,000.00View SEC Filing  
5/6/2014Glenn MuirCFOSell196,000$23.29$4,564,840.00View SEC Filing  
5/6/2014Lawrence LevyDirectorSell5,052$23.58$119,126.16View SEC Filing  
5/6/2014Robert LavalleeCAOSell22,796$23.58$537,529.68View SEC Filing  
3/14/2014David Lavance, Jr.DirectorSell5,500$21.49$118,195.00View SEC Filing  
3/14/2014Glenn MuirCFOSell160,000$21.51$3,441,600.00View SEC Filing  
3/7/2014Mark CaseyCAOSell3,251$22.53$73,245.03View SEC Filing  
2/11/2014Stephen MacmillanCEOBuy38,600$21.58$832,988.00View SEC Filing  
2/7/2014Stephen MacmillanCEOBuy198,900$20.78$4,133,142.00View SEC Filing  
12/13/2013Robert LavalleeCAOSell15,677$21.70$340,190.90View SEC Filing  
10/30/2013Glenn P MuirCFOSell140,000$22.32$3,124,800.00View SEC Filing  
10/15/2013Glenn P MuirCFOSell28,000$22.12$619,360.00View SEC Filing  
9/16/2013Glenn MuirCFOSell28,000$20.45$572,600.00View SEC Filing  
9/13/2013Robert LavalleeCAOSell2,500$20.33$50,825.00View SEC Filing  
8/20/2013David BradySVPSell42,328$22.80$965,078.40View SEC Filing  
8/15/2013Glenn MuirCFOSell28,000$22.49$629,720.00View SEC Filing  
8/8/2013Lawrence LevyDirectorSell5,000$22.50$112,500.00View SEC Filing  
8/8/2013Mark CaseyCAOSell14,804$22.57$334,126.28View SEC Filing  
7/19/2013Robert H LavalleeCAOSell11,254$20.89$235,096.06View SEC Filing  
7/15/2013Glenn P MuirCFOSell28,000$19.78$553,840.00View SEC Filing  
7/1/2013Robert CascellaCEOSell20,000$19.55$391,000.00View SEC Filing  
6/17/2013Glenn P MuirCFOSell28,000$21.42$599,760.00View SEC Filing  
6/3/2013Robert CascellaCEOSell20,000$20.71$414,200.00View SEC Filing  
2/25/2013Lawrence M LevyDirectorSell5,000$22.00$110,000.00View SEC Filing  
9/5/2012Glenn P MuirCFOSell68,750$19.96$1,372,250.00View SEC Filing  
8/8/2012Glenn P MuirCFOSell68,750$19.69$1,353,687.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Hologic (NASDAQ:HOLX)
Latest Headlines for Hologic (NASDAQ:HOLX)
americanbankingnews.com logoQ1 2018 Earnings Forecast for Hologic, Inc. Issued By Leerink Swann (HOLX)
www.americanbankingnews.com - October 16 at 5:38 AM
americanbankingnews.com logoAnalyzing Hologic (HOLX) & Its Rivals
www.americanbankingnews.com - October 16 at 2:10 AM
americanbankingnews.com logoBrokers Set Expectations for Hologic, Inc.'s FY2018 Earnings (HOLX)
www.americanbankingnews.com - October 13 at 1:30 PM
americanbankingnews.com logoInsider Selling: Hologic, Inc. (HOLX) Director Sells 9,596 Shares of Stock
www.americanbankingnews.com - October 12 at 7:26 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for Hologic, Inc.'s Q1 2018 Earnings (HOLX)
www.americanbankingnews.com - October 11 at 10:12 AM
americanbankingnews.com logoHologic, Inc. (HOLX) Director Sells $266,818.44 in Stock
www.americanbankingnews.com - October 10 at 7:38 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - October 10 at 2:34 PM
americanbankingnews.com logoStifel Nicolaus Lowers Hologic, Inc. (HOLX) Price Target to $45.00
www.americanbankingnews.com - October 9 at 8:16 AM
americanbankingnews.com logoHologic, Inc. (HOLX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 8 at 9:00 AM
nasdaq.com logoHologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval - Nasdaq
www.nasdaq.com - October 6 at 8:02 PM
finance.yahoo.com logoHologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval
finance.yahoo.com - October 6 at 8:01 PM
americanbankingnews.com logo Analysts Anticipate Hologic, Inc. (HOLX) Will Post Earnings of $0.49 Per Share
www.americanbankingnews.com - October 6 at 4:36 PM
streetinsider.com logoHologic (HOLX) Says Panther Fusion Flu A/B/RSV Assay is Now FDA Cleared
www.streetinsider.com - October 6 at 8:02 AM
streetinsider.com logoHologic (HOLX) Says Panther Fusion Flu A/B/RSV Assay is Now FDA Cleared - StreetInsider.com
www.streetinsider.com - October 5 at 7:57 PM
finance.yahoo.com logoPanther Fusion® Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion® System
finance.yahoo.com - October 5 at 7:57 PM
finance.yahoo.com logoHologic, Inc. -- Moody's assigns Ba3 to Hologic's senior unsecured bonds
finance.yahoo.com - October 5 at 2:56 PM
finance.yahoo.com logoHologic Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 4.375% Senior Notes Due 2025
finance.yahoo.com - October 5 at 2:56 PM
finance.yahoo.com logoHologic to Announce Financial Results for the Fourth Quarter of Fiscal 2017 on Wednesday, November 8, 2017
finance.yahoo.com - October 4 at 9:20 AM
finance.yahoo.com logoHologic Enters into Amended and Restated Five-Year Secured Credit Agreement
finance.yahoo.com - October 4 at 9:20 AM
finance.yahoo.com logoHologic Announces Offering of $350 Million of Senior Notes Due 2025
finance.yahoo.com - October 4 at 9:20 AM
finance.yahoo.com logoIs Hologic Inc’s (HOLX) PE Ratio A Signal To Buy For Investors?
finance.yahoo.com - October 4 at 9:20 AM
finance.yahoo.com logoHologic, Inc. -- Moody's assigns Ba1 to Hologic's senior secured credit facility
finance.yahoo.com - October 4 at 9:20 AM
americanbankingnews.com logoHologic, Inc. (HOLX) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - October 2 at 4:30 PM
finance.yahoo.com logoHologic CEO: Next-gen mammograms improve patient experien...
finance.yahoo.com - October 2 at 1:32 PM
nasdaq.com logoHologic, Inc. (Nasdaq: HOLX) to Ring The Nasdaq Stock Market Opening Bell
www.nasdaq.com - September 29 at 4:49 PM
bizjournals.com logoHologic CEO Steve MacMillan to Ring Nasdaq Opening Bell on October 2 to Kick Off Breast Cancer Awareness Month
www.bizjournals.com - September 29 at 10:19 AM
bizjournals.com logoHologic Introduces a More Comfortable Mammogram with the Launch of the SmartCurve™ Breast Stabilization System
www.bizjournals.com - September 28 at 12:59 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Receives Hold Rating from Royal Bank Of Canada
www.americanbankingnews.com - September 22 at 9:38 PM
americanbankingnews.com logo$792.67 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter
www.americanbankingnews.com - September 19 at 1:16 AM
finance.yahoo.com logoNew USPSTF Draft Cervical Cancer Screening Recommendations Are a Step Back for Women's Health, Would Put Lives at Risk
finance.yahoo.com - September 14 at 8:27 PM
americanbankingnews.com logoFinancial Survey: Hologic (HOLX) versus Intuitive Surgical (ISRG)
www.americanbankingnews.com - September 13 at 4:44 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 13 at 9:34 AM
americanbankingnews.com logoWilliam Blair Weighs in on Hologic, Inc.'s Q4 2017 Earnings (HOLX)
www.americanbankingnews.com - September 13 at 9:02 AM
nasdaq.com logoHologic (HOLX) Down 11.1% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - September 12 at 11:32 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Director Sells $278,706.56 in Stock
www.americanbankingnews.com - September 11 at 7:50 PM
finance.yahoo.com logoHologic (HOLX) Down 11.1% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 11 at 4:39 AM
finance.yahoo.com logoGMAC Commercial Mortgage Securities, Inc. Series 2003-C1 -- Moody's Affirms Five Classes of GMACC 2003-C1
finance.yahoo.com - September 8 at 8:07 PM
nasdaq.com logoHologic (HOLX) Launches Brevera, Progresses in Breast Health - Nasdaq
www.nasdaq.com - September 6 at 6:08 AM
americanbankingnews.com logo Analysts Expect Hologic, Inc. (HOLX) Will Announce Quarterly Sales of $792.68 Million
www.americanbankingnews.com - September 1 at 9:22 PM
finance.yahoo.com logoHologic Announces Availability of New Brevera® Breast Biopsy System with CorLumina® Imaging Technology
finance.yahoo.com - August 31 at 7:29 PM
finance.yahoo.com logoKahn Brothers Curbs Hologic, Citigroup, Pfizer Postitions, Exits GE
finance.yahoo.com - August 31 at 5:50 AM
nasdaq.com logoHologic Enters Oversold Territory (HOLX)
www.nasdaq.com - August 28 at 7:12 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Short Interest Down 13.8% in August
www.americanbankingnews.com - August 27 at 3:12 AM
nasdaq.com logoAfter Hours Most Active for Aug 22, 2017 : CPN, CRM, QQQ, KO, AAPL, SBUX, T, MU, TGT, XOM, CSCO, HOLX - Nasdaq
www.nasdaq.com - August 23 at 12:58 AM
americanbankingnews.com logoCritical Survey: Hologic (HOLX) vs. Invivo Therapeutics Holdings Corp (NVIV)
www.americanbankingnews.com - August 21 at 4:22 AM
americanbankingnews.com logoHologic, Inc. (HOLX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 19 at 9:12 AM
finance.yahoo.com logoHologic, Inc. – Value Analysis (NASDAQ:HOLX) : August 12, 2017
finance.yahoo.com - August 12 at 6:38 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Hologic Inc.
finance.yahoo.com - August 9 at 7:47 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Director Sells $276,908.24 in Stock
www.americanbankingnews.com - August 7 at 8:02 PM
americanbankingnews.com logoFY2018 EPS Estimates for Hologic, Inc. Reduced by Analyst (HOLX)
www.americanbankingnews.com - August 7 at 9:06 AM



Hologic (HOLX) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.